Table 4.

Clinical characteristics of the FGF23 trajectory groups at the onset of the survival time (time 0) in the primary five-time point trajectory analysis

CharacteristicsOverall, n=1309FGF23 Trajectory Group
Stable, lnFGF23 per 1 yr =0.03, n=724Slowly Rising, lnFGF23 per 1 yr =0.14, n=486Rapidly Rising, lnFGF23 per 1 yr =0.46, n=99
Age, yr62.6±10.862.4±10.663.2±11.061.5±10.9
Women, %43.440.746.348.5
Black, %43.241.246.343.4
Hispanic, %11.98.415.221.2
Current smoking, %11.48.714.117.8
BMI, kg/m232.2±8.331.7±7.932.8±8.832.1±8.8
SBP, mm Hg127.3±23.3126.2±22.1128.6±24.5129.3±25.3
Diabetes, %53.447.560.163.4
Heart failure, %17.911.424.035.4
Stroke, %12.59.615.619.2
Peripheral vascular disease, %12.17.915.824.8
Coronary artery disease, %32.627.238.643.2
eGFR, ml/min per 1.73 m240.0±17.445.8±16.633.2±15.431.4±16.7
UACR, mg/ga52.6 (9.3–457.5)18.3 (5.8–133.8)185.1 (27.9–887.1)809.6 (105.7–2025.1)
Hemoglobin, g/dl12.4±1.812.8±1.812.0±1.811.6±1.8
Serum albumin, g/dl3.9±0.43.9±0.43.8±0.43.8±0.5
Calcium, mg/dl9.3±0.69.3±0.59.3±0.69.3±0.6
Phosphate, mg/dl4.2±0.94.0±0.84.3±1.04.7±1.1
PTH, pg/ml99.2 (51.4–178.1)75.5 (42.1–143.9)126.4 (72.3–208.5)153.2 (85.5–227.7)
Baseline FGF23, RU/ml145.0 (96.0–231.8)105.2 (80.2–139.9)214.3 (159.8–304.0)471.9 (334.8–749.1)
Final FGF23, RU/ml259.0 (120.7–1211.9)134.1 (88.1–241.0)584.5 (294.5–1612.6)2124.5 (1027.4–7186.4)
eGFR slope, ml/min per 1.73 m2 per year0.0±2.20.7±2.0−0.7±2.1−1.9±1.7
Serum phosphate slope, mg/dl per year−0.02 (−0.05 to 0.03)−0.03 (−0.06 to 0.00)0.00 (−0.03 to 0.05)0.07 (0.02 to 0.12)
  • Results are reported as proportions, means±SD, or medians (interquartile ranges). BMI, body mass index; SBP, systolic BP; RU, reference unit.

  • a UACR is from the CRIC Study baseline visit.